



The 10th International Meeting on Neuroacanthocytosis Syndromes was held online on 
March 10th–12th, 2021. The COVID19 pandemic situation made our planned meeting in 
Barcelona on March 2020 to be suspended by one year, and finally took place online. The 
meeting followed the previous nine international symposia, the last of which was held in 
Dresden, Germany in March, 2018. The setting of the meeting encouraged interactions, 
exchange of ideas and networking opportunities among the high number of participants 
from around the globe, including scientists, neurologists and specially patients and 
caregivers. A total of 27 oral communications were distributed in 8 sessions with topics 
ranging from molecular and cellular functions of VPS13 genes and proteins, their 
involvement in Neuroacanthocytosis Syndromes and finally clinical aspects and patients 
care. In addition, 5 posters were presented. Altogether, scientists and neurologists 
discussed recent advances and set the bases for next steps, action points, and future 
studies in close collaboration with the patient’s associations, which are always actively 
involved in the whole process.
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INTRODUCTION
Neuroacanthocytosis syndromes are rare disorders that 
include acanthocytosis of red blood cells, and neurological 
manifestations such as chorea, epilepsy, and problems 
with mood, thinking and memory. Mutations in the VPS13A 
and XK genes cause chorea-acanthocytosis (ChAc) and 
McLeod syndrome, respectively. These two syndromes 
were the focus of most of the talks during the meeting, 
although the involvement of other VPS13 genes in several 
“VPS13opathies” were also presented and discussed. 
Detailed clinical phenotyping, genetic analysis, Western 
blot diagnosis (in the case of VPS13A) and biomarkers 
such as creatine kinase (CK) elevation and red blood cell 
sedimentation, emerged as key elements that might 
be used to detect, diagnose and follow progression 
of the syndromes. Common cellular and molecular 
mechanisms between the different VPS13opathies were 
present throughout the meeting. These include the role 
of the different VPS13s in mediating lipid transport in 
membrane contact sites, as well as their involvement in 
mitochondria, endoplasmic reticulum, lipid droplet and 
endosomal functions. Direct interactions between VPS13A 
and XK proteins may explain some of the common features 
between ChAc and McLeod syndrome. Also, the relation 
between VPS13A function and Lyn, PIP3 and IDH3A 
signaling, together with calcium modulation in the cell may 
provide potential therapeutic targets for ChAc treatment. 
Finally, recent insights in VPS13A distribution in the mouse 
brain, and advances in the phenotyping of mouse models of 
ChAc, were described and might pave the way for improved 
understanding ChAc pathophysiology.
At the therapeutic level, outcomes from 
pharmacological targeting of Lyn kinase and PI3K 
pathway were detailed, and indicated positive effects 
in treating red cell blood alterations in patients but 
not central nervous system symptoms. Deep brain 
stimulation of globus pallidus was suggested as 
palliative treatment for patients. Because of the low 
number of patients worldwide, sharing information 
regarding patients was encouraged and, in this regard, 
improvements on the neuroacanthocytosis case registry 
database were discussed, with the aim of re-activating 
its use and ensure its continuity for the benefit of all 
the community. Importantly, patients and caregivers 
received professional advices for improving their 
respective quality of lives.
As with our recent symposia, basic scientists and 
clinicians discussed recent advances and set the bases 
for next steps, action points, and future studies, in close 
collaboration with the patient associations, which are 
always actively involved.
NEW DEVELOPMENTS IN TRANSLATIONAL 
RESEARCH
New developments in translational research
Jordi Alberch1,2,3, Manuel J Rodríguez1,2,3 and Mercè Masana1,2,3
1. Dept. Biomedical Sciences, Institute of Neurosciences, 
School of Medicine and Health Sciences, Universitat de 
Barcelona, Barcelona, Spain
2. Institut d’Investigacions Biomèdiques August Pi i Sunyer 
(IDIBAPS), Barcelona, Spain
3. Centro de Investigación Biomédica en Red sobre 
Enfermedades Neurodegenerativas (CIBERNED), Madrid, 
Spain.
Abstract
Twenty years ago, it was discovered a conserved sorting-
associated protein (VPS13A) that was mutant in chorea-
acanthocytosis (ChAc). The lack of this protein triggers 
a cascade of intracellular events leading to selective 
neurodegeneration, mainly in the brain. However, the 
molecular and cellular function of VPS13 proteins only 
recently start to emerge. VPS13 is a peripheral membrane 
protein that transfer lipids between organelles, and it is 
localized at membrane contact sites between endoplasmic 
reticulum, vacuole, endosome and mitochondria. The 
mutations in VPS13 can produce also several intracellular 
defects such as actin polymerization, autophagy, and 
mitochondria integrity. Interestingly, it has been recently 
described that dysregulation of a VPS13A-XK complex is 
the common basis for ChAc and McLeod Syndrome.
In spite of these studies about the function of VPS13A, 
little is known about the function of this protein in the nervous 
system and why this mutation is affecting specific neuronal 
populations. In mouse brain, VPS13A is predominantly 
localized to microsomal and synaptosomal fractions, 
neuronal perinuclear region, cytoplasm, and fibers. In any 
case, the expression levels and subcellular localization of the 
protein cannot explain the specific neuronal vulnerability. 
Interestingly, recent studies have provided new data 
thanks to the differentiation of iPSCs generated from skin 
biopsies of ChAc patients, describing mechanisms involved 
in neuronal survival and calcium homeostasis. Interestingly, 
a recent study using a transcriptomic analysis showed 
that VPS13A is involved in tolerance to cocaine-induced 
motor disturbances, with a differential regulation between 
the dorsal and ventral striatum. Thus, next step must be 
focused to study the effect of the lack of VPS13A in the 
brain to understand how the mutation can affect neuronal 
connectivity between the different neuronal populations 
and the mechanisms that control the selective vulnerability.
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NEUROACANTHOCYTOSIS SYNDROMES 
AND VPS13OPATHIES
Neuroacanthocytosis syndromes and 
VPS13opathies: the pathophysiological 
spectrum
Andreas Hermann1,2,3
1. Translational Neurodegeneration Section “Albrecht-
Kossel”, Department of Neurology, University Medical 
Center Rostock, University of Rostock, Rostock, Germany. 
2. DZNE, German Center for Neurodegenerative Diseases, 
Research Site Rostock/Greifswald, Rostock, Germany.
3. Center for Transdisciplinary Neurosciences Rostock 
(CTNR), University Medical Center Rostock, University of 
Rostock, Rostock, Germany.
Abstract
Chorea-Acanthocytosis (ChAc) is one of the core 
neuroacanthocytosis (NA) syndromes characterized by 
a movement disorder and blood cell acanthocytosis. 
The other main NA syndrome is McLeod syndrome 
with mutations in the XK gene, besides rare variants 
of NA such as Pantothenate kinase-associated 
neurodegeneration (PKAN), Huntington disease-like 2 or 
Abeta-/hypolipoproteinaemia syndromes besides others. 
This clinically associated syndromes originate from very 
different genetic alterations.
ChAc is an ultra-rare neurodegenerative disease caused 
by mutations in the VPS13A gene (vacuolar protein-
sorting protein 13). VPS13A belongs to a gene family of 
four members (VPS13 A-D), for which only one orthologue 
exist in yeast (vsp13). This prompted speculations since 
many years about the other VPS13opathies also possibly 
being associated to neurological diseases. Mutations in 
VPS13B (COH1) are known to cause Cohen syndrome, a 
developmental disorder with intellectual disability and 
distinct craniofacial abnormalities. Recent developments 
identified VPS13C and D as disease causing mutations in 
other movement disorders, namely mutations in VPS13C 
cause autosomal recessive Parkinson’s disease/Lewy body 
disease and VPS13D mutations cause spinocerebeller 
ataxia with saccadic intrusions (SCAR4).
Pathophysiologically, mammalian VPS13 A-D family 
members descend from one vps13 orthologue in yeast. Also 
mechanistically, there are somehow connected in cellular 
(patho-) physiology. While affecting different organelles and 
different proteins, they all are more or less connected to 
lipids and membrane shuttling within or between organelles. 
The talk will give current insights in the clinical and 
molecular diversity and overlap on the VPS13inopathies and 
suggests that the genetic/molecular classification towards 
VPS13inopathies rather than to neuroacanthocytosis 
syndromes might be helpful in developing future 
(molecular) disease modifying treatments.
Clinical aspects of chorea-acanthocytosis 
and McLeod syndrome
Ruth H. Walker1,2
1. Department of Neurology, James J. Peters Veterans 
Affairs Medical Center, Bronx, NY, USA.
2. Department of Neurology, Mount Sinai School of 
Medicine, New York City, NY, USA.
Abstract
Neuroacanthocytosis syndromes are characterized by 
the presence of acanthocytes – abnormally contracted 
red blood cells with thorny protrusions, in addition to 
neurological symptoms. These inherited disorders involve 
basal ganglia neurodegeneration and typically present 
with a spectrum of movement disorders, including 
chorea, dystonia, tics, and parkinsonism. A range of 
psychopathologic features can be seen, including 
depression, psychosis, cognitive impairment, disinhibition, 
and obsessive-compulsive behaviors. Neurologic signs 
which distinguish these disorders from other basal 
ganglia conditions include seizures and peripheral 
neuropathy. The typical “rubber person” gait is due to a 
combination of dystonia, neuropathy, and probably motor 
impersistence. Dysarthria can be prominent and very 
disabling. Dysphagia requires ongoing management to 
minimize risks of aspiration pneumonia. Elevated creatine 
kinase and liver enzyme abnormalities can suggest either 
diagnosis. Neuroimaging demonstrates atrophy of the 
caudate nucleus and putamen. Acanthocytes are variably 
present and can be absent. Chorea-acanthocytosis is an 
autosomal recessive syndrome caused by mutations 
of the gene encoding for the protein chorein. Patients 
typically present with a combination of symptoms 
in young adulthood which slowly progress over 1–2 
decades. Prominent orofacial dyskinesia and swallowing 
dystonia suggests the diagnosis, as does self-mutilating 
tongue- and lip-biting. The diagnosis can be made by 
Western blot demonstrating the absence of the protein 
in peripheral blood. McLeod syndrome is an X-linked 
recessive disorder, caused by mutations of the gene 
encoding for the McLeod protein XK. Cardiomyopathy 
and hepatosplenomegaly are distinguishing features; 
the former should be annually monitored to reduce 
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complications. Presentation is usually in middle age, and 
can be quite variable, with a slow rate of progression. The 
diagnosis is made by antigen profiling of the erythrocyte, 
demonstrating absent expression of XK and decreased 
expression of Kell antigens.
Bloody jello: Colloidal physics 
explains acanthocyte sedimentation 
rate as a diagnostic biomarker for 
neuroacanthocytosis 
Alexis Darras1, Kevin Peikert2,3, Antonia Rabe1,4, François 
Yaya1,5, Greta Simionato1,6, Thomas John1, Anil Kumar 
Dasanna7, Semen Buvalyy7, Jürgen Geisel8, Andreas 
Hermann2,3,9,10, Dmitry A. Fedosov7, Adrian Danek11, Christian 
Wagner1,12 and Lars Kaestner1,4
1. Experimental Physics, Saarland University, 66123 
Saarbruecken, Germany.
2. Translational Neurodegeneration Section “Albrecht-
Kossel”, Department of Neurology, University Medical 
Center Rostock, University of Rostock, Rostock, Germany.
3. Neurodegenerative Diseases, Department of Neurology, 
Technische Universität Dresden, Dresden, Germany.
4. Theoretical Medicine and Biosciences, Saarland 
University, 66424 Homburg, Germany. 
5. Laboratoire Interdisciplinaire de Physique, UMR 5588, 
38402 Saint Martin d’Hères, France. 
6. Institute for Clinical and Experimental Surgery, Saarland 
University, 66424 Homburg, Germany. 
7. Institute of Biological Information Processing and 
Institute for Advanced Simulation, Forschungszentrum 
Jülich, 52425 Jülich, Germany.
8. Institute for Clinical and Experimental Surgery, Saarland 
University, 66424 Homburg, Germany.
9. DZNE, German Center for Neurodegenerative Diseases, 
Research Site Rostock/Greifswald, Rostock, Germany.
10. Center for Transdisciplinary Neurosciences Rostock 
(CTNR), University Medical Center Rostock, University of 
Rostock, Rostock, Germany. 
11. Neurologische Klinik und Poliklinik, Ludwig-Maximilians-
Universität, 81366 Munich, Germany. 
12. Physics and Materials Science Research Unit, University 
of Luxembourg, Luxembourg City, Luxembourg.
Abstract
Background: Chorea-acanthocytosis (ChAc) and 
McLeod syndrome (MLS) are the core diseases of rare 
congenital neurodegenerative disorders summarized as 
neuroacanthocytosis syndrome (NAS). NAS patients have 
an increased number of irregular spiky erythrocytes, so-
called acanthocytes. The detection of acanthocytes is 
error-prone and often leads to misdiagnosis of NAS. 
Methods: Blood samples were collected from 6 ChAc, 3 MLS 
patients and 8 healthy donors. The standard Westergren 
method was used to record detailed erythrocyte 
sedimentation rate (ESR) curves. To address the mechanism 
involved we (i) manipulated ESR conditions (dextran- and 
saline solutions, plasma swap), (ii) performed optical 
investigations (e.g., 3D-confocal microscopy, aggregation 
force measurements with holographic optical tweezers) 
and (iii) performed theoretical modelling. 
Results: The 2h ESR distance of 10 mm is a threshold to 
differentiate NAS patients and healthy donors without 
overlap. Colloidal physics provides a mechanistic 
explanation with the hole size of the percolating network 
(patients: 5.67 ± 0.57 µm vs. control: 8.53 ± 1.53 µm; p = 
0.0045) as a characteristic value. Both erythrocytes and 
plasma properties contribute to the prolonged ESR. The 
plasma of patients has lower fibrinogen level (patients: 233 
± 38 mg/dl vs. control: 303 ± 46 mg/dl; p = 0.0034) resulting 
on lower aggregation forces (1.16 ± 0.97 pN vs. 4.79 ± 1.56 
pN; p = 0.0005).
Conclusion: The ESR is a clear and robust diagnostic marker 
for ChAc and MLS that can easily be integrated into the 
standard diagnosis of patients with neurodegenerative 
symptoms. In addition, this study is a hallmark of the 
physical view of the erythrocyte sedimentation process by 
describing anticoagulated blood in stasis as a percolating 
gel, allowing the application of colloidal physics theory.
McLeod Syndrome – an overview
Hans H Jung1




McLeod syndrome (MLS) is a relentlessly X-linked 
progressive neurodegenerative disorder characterized by 
a progressive choreatic movement disorder and possible 
psychiatric as well as cognitive manifestations. Additional 
manifestations include peripheral neuropathy, neurogenic 
muscle atrophy, myopathy as well as cardiological 
involvement. Most patients have diminished and absent 
tendon reflexes and elevated serum levels of creatine 
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kinase. Blood smears may demonstrate red blood cell 
acanthocytosis, which lead to the assumption of so-called 
neuroacanthocytosis syndromes, along with the VPS13A 
disease choreoacanthocytosis (ChAc), with which MLS 
shares a considerable phenotypic overlap. Diagnosis of MLS 
bases on the typical phenotype, presence of CK elevation 
and possible red cell acanthocytosis. The diagnosis is 
confirmed by presence of the so-called McLeod blood 
group phenotype (absent Kx antigen, weakened or absent 
Kell antigens) and molecular genetic confirmation of a 
pathogenetic alteration in the disease causing XK gene. 
Management of MLS is led by the individual symptoms. Of 
note, possible transfusion reactions should be respected 
and autologous blood donations might be attempted. In 
addition, regular cardiological follow-up examinations 
are mandatory.
VPS13 GENES IN MOVEMENT DISORDERS
Genetics of Chorea-Acanthocytosis: 
the example of Spanish patients 
Antonio Velayos-Baeza1,2
1 Wellcome Centre for Human Genetics, University of 
Oxford, Oxford, UK.
2 Dept. of Physiology, Anatomy and Genetics, University of 
Oxford, Oxford, UK.
Abstract
Chorea-Acanthocytosis (ChAc), one of the core 
Neuroacanthocytosis syndromes, is an adult-onset rare 
neurodegenerative disorder caused by alteration in gene 
VPS13A, one of the four members of the human gene 
family presenting similarity to yeast VPS13 gene; all of 
these genes have now been associated with recessive 
disorders.
Extensive screening in affected patients revealed 
ChAc results from a wide range of pathogenic variations, 
including large deletions/duplications, splicing-site 
mutations, small insertions/deletions, nonsense mutations, 
or missense mutations, with a gene-wide distribution and 
no hot-spots. These studies provided important insight 
about this disorder, including the following. First, despite 
several RNA transcript variants having been described, only 
the major A variant, originally described as including exons 
1–68+70–73, appears to be directly associated with ChAc. 
Second, most pathogenic variations lead to absence of 
the VPS13A protein (chorein), confirming that this disease 
results from loss-of-function of chorein; this allowed to 
develop a semi-diagnostic test based on the analysis 
by western blotting of protein extracts from blood, an 
approach much faster and cheaper than DNA sequencing. 
Third, a relatively small number of the described pathogenic 
variations are missense mutations, suggesting that some 
of the affected residues might be particularly relevant for 
the function or the stability of chorein. Fourth, despite a 
number of reports about the occurrence of “dominant 
ChAc” (patients presenting with ChAc syndrome but having 
only one VPS13A allele mutated), the current scientific data 
only support the recessive nature of this condition.
The above points will be among those discussed in a 
presentation about the current knowledge on the genetics 
of ChAc in general. As an example to illustrate some of 
these points, specific details will be presented on the 
genetics of Spanish patients, one of the largest groups of 
studied ChAc cases, in which many of the different types of 
pathogenic variations have been found.
Chorein Western blot diagnosis and 
VPS13A mutation searching
Gabriel Miltenberger-Miltenyi1
1. Department of Neurology, Ludwig-Maximilians-
Universität München, Munich, Germany.
Abstract
As of 2020, with the help of a large group of international 
colleagues, we have collected blood samples of more than 
700 patients with a clinical suspicion of VPS13A disease 
(formerly chorea-acanthocytosis, ChAc) or related disorders 
(Danek, Bader & Miltenberger).
So far, we confirmed a diagnosis of VPS13A disease by 
Western blot of the chorein protein in 190 patients. Our 
free diagnostic chorein Western blot service is generously 
financed by the Advocacy for Neuroacanthocytosis 
patients. We have started to compare different protein 
detection protocols to achieve the most reliable approach 
for protein-based diagnosis of VPS13A disease. Results 
from the currently run batch of 80 samples will be 
presented. In parallel, we analyze the VPS13A gene to 
gain more information about the associations between 
genetic changes and chorein levels. In the first analysis of 
patients with normal chorein (22 cases), we have detected 
mutations in six patients. In four patients a core neuro-
acanthocytosis syndrome was diagnosed: in two patients 
each from mutations in the VPS13A gene (confirming the 
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diagnosis of VPS13A disease) and from mutations in the 
XK gene, associated with McLeod syndrome. Two patients 
showed variants in genes associated with other types of 
movement disorders (KMT2B, GNAL). Overall, we have 
currently observed six cases with known VPS13A mutations 
in the presence of normal appearing chorein bands in 
Western blotting and discuss the details in a dedicated 
presentation at this meeting (Miltenberger et al.). To 
systematically catalogue all known VPS13A mutations, 
we joined the widely used open access LOVD (Leiden 
Open Variation Database) as curators for the VPS13A gene 
(Miltenberger, Velayos-Baeza & Danek: https://databases.lovd.
nl/shared/genes/VPS13A).
The role of VPS13C and VPS13D genes in 
the pathogenesis of movement disorders
Coro Paisán-Ruíz1
1. Department of Neurology, Icahn School of Medicine at 
Mount Sinai, New York, USA.
Abstract
Pathogenic genetic variations within VPS13C and VPS13D 
genes have recently been identified in movement disorder 
phenotypes. An overview of the disease-associated 
phenotypes and genetic variations will be summarized here 
to assist in the clinical diagnosis of prospective patients and 
families.
Contribution of rare homozygous 
and compound heterozygous VPS13C 
missense mutations to dementia with 
Lewy bodies and Parkinson’s disease 
Stefanie Smolders1,2,3, Stéphanie Philtjens1,2,3, David 
Crosiers1,2,3,4, Anne Sieben1,2,6, Elisabeth Hens1,2,3,4,5, Bavo 
Heeman1,2,3, Sara Van Mossevelde1,2,4,5, Philippe Pals2,4, Bob 
Asselbergh1,2,3, Roberto Dos Santos Dias7, Yannick Vermeiren2,3, 
Rik Vandenberghe8, Sebastiaan Engelborghs2,3,9, Peter Paul De 
Deyn2,3,5, Jean-Jacques Martin2, Patrick Cras2,3,4, Wim Annaert7, 
Christine Van Broeckhoven1,2,3, and BELNEU consortium.
1. Center for Molecular Neurology, VIB, Antwerp, Belgium.
2. Institute Born-Bunge, Antwerp, Belgium.
3. University of Antwerp, Antwerp, Belgium.
4. Department of Neurology, University Hospital Antwerp, 
Edegem, Belgium.
5. Department of Neurology, Hospital Network Antwerp, 
Antwerp, Belgium.
6. Department of Neurology, University Hospital Ghent and 
University of Ghent, Ghent, Belgium.
7. Center for Brain and Disease Research VIB, and 
Department of Neurosciences KU Leuven, Leuven, Belgium.
8. Department of Neurology, University Hospitals Leuven and 
Department of Neurosciences, KU Leuven, Leuven, Belgium.
9. Department of Neurology, UZ Brussel and Center for 
Neurosciences, Vrije Universiteit Brussel (VUB), Brussels, 
Belgium.
Abstract
Dementia with Lewy bodies (DLB) and Parkinson’s disease 
(PD) are clinically, pathologically and etiologically disorders 
embedded in the Lewy body disease (LBD) continuum,1 
characterized by neuronal α-synuclein pathology. Rare 
homozygous and compound heterozygous premature 
termination codon (PTC) mutations in the Vacuolar Protein 
Sorting 13 homolog C gene (VPS13C) are associated with 
early-onset recessive PD. We observed in two siblings with 
early-onset age (<45) and autopsy confirmed DLB, compound 
heterozygous missense mutations in VPS13C, p.Trp395Cys 
and p.Ala444Pro, inherited from their healthy parents in a 
recessive manner. In lymphoblast cells of the index patient, 
the missense mutations reduced VPS13C expression by 
90% (p = 0.0002). Subsequent, we performed targeted 
resequencing of VPS13C in 844 LBD patients and 664 control 
persons. Using the optimized sequence kernel association 
test, we obtained a significant association (p = 0.0233) of rare 
VPS13C genetic variants (minor allele frequency ≤ 1%) with 
LBD. Among the LBD patients, we identified one patient with 
homozygous missense mutations and three with compound 
heterozygous missense mutations in trans position, indicative 
for recessive inheritance. In four patients with compound 
heterozygous mutations, we were unable to determine trans 
position. The frequency of LBD patient carriers of proven 
recessive compound heterozygous missense mutations is 
0.59% (5/844). In autopsy brain tissue of two unrelated LBD 
patients, the recessive compound heterozygous missense 
mutations reduced VPS13C expression. Overexpressing 
of wild type or mutant VPS13C in HeLa or SH-SY5Y 
cells, demonstrated that the mutations p.Trp395Cys or 
p.Ala444Pro, abolish the endosomal/lysosomal localization 
of VPS13C. Overall, our data indicate that rare missense 
mutations in VPS13C are associated with LBD and recessive 
compound heterozygous missense mutations might have 
variable effects on the expression and functioning of VPS13C. 
We conclude that comparable to the recessive inherited 
PTC mutations in VPS13C, combinations of rare recessive 
compound heterozygous missense mutations reduce VPS13C 
expression and contribute to increased risk of LBD.
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VPS13 PROTEINS IN CELL PROCESSES 
Targeting VPS13 proteins to membrane 
contact sites
Samantha K. Dziurdzik1, Michael Davey1 and Elizabeth 
Conibear1
1. Department of Medical Genetics, University of British 
Columbia, Vancouver, Canada.
Abstract
Mutations in each of the four human VPS13 (VPS13A-D) 
proteins are associated with distinct neurological disorders: 
Chorea acanthocytosis, Cohen syndrome, early-onset 
Parkinson’s disease and spastic ataxia. Recent evidence 
suggests that the different VPS13 paralogs transport lipids 
between organelles at different membrane contact sites. 
However, how each VPS13 isoform is targeted to these 
different sites is not known. Yeast has a single Vps13 protein 
whose localization depends on developmental stage or 
nutrient conditions. We have found that the membrane 
localization of yeast Vps13 requires a conserved six-repeat 
region, the Vps13 Adaptor Binding (VAB) domain, which 
binds to organelle-specific adaptors. Our results suggest 
that all adaptors compete for a single binding site in the 
VAB domain. Using a systematic mutagenesis strategy to 
define the contribution of each repeat, we have identified 
the putative adaptor binding site. Importantly, missense 
disease-causing mutations are predicted to impact this 
binding site, suggesting a conserved adaptor binding 
role for the VAB domain. Current efforts are focused on 
identifying novel VAB binding partners in both yeast and 
humans.
VPS13, the founding member of a protein 
family that mediates bulk lipid transfer at 
intracellular membrane contact sites
Marianna Leonzino1,2,3,*, Karin Reinisch2 and Pietro De 
Camilli1,2,3
1. Department of Neuroscience, Yale University School of 
Medicine, New Haven, CT, USA.
2. Department of Cell Biology, Yale University School of 
Medicine, New Haven, CT, USA.
3. Howard Hughes Medical Institute, Yale University School 
of Medicine, New Haven, CT, USA.
* Present address: CNR, Institute of Neuroscience at 
Humanitas Research Hospital, Milan, Italy.
Abstract
The VPS13 protein family has been implicated in a variety 
of cellular function. While in yeast all these functions are 
performed by a single VPS13 gene, mammalian genomes 
encode 4 different VPS13 proteins whose physiological 
roles differ and whose mutations result in distinct, 
generally severe, clinical conditions. However, as our 
recent studies suggest, the shared core function of all 
these proteins, and of the related protein ATG2, is to act 
as conduits for the bulk flow of lipids at sites of contacts 
between intracellular membranes. They do so by acting as 
bridges that tether two adjacent membranes and allow 
lipid flux along a hydrophobic groove that spans their 
entire length. Two of the mammalian VPS13 isoforms, 
VPS13A and VPS13D, whose loss-of-function mutations 
cause Chorea Acanthocytosis and heterogeneous 
movement disorders including ataxias, respectively, act 
at contacts between the ER and mitochondria, although 
they bind to mitochondria via different mechanisms. Such 
localization is consistent with the redundant role of yeast 
VPS13 and ERMES, a protein complex that mediates lipid 
transport between the ER and mitochondria, even though 
yeast VPS13 itself populates contact sites other than 
those between ER and mitochondria (PMID: 26370498; 
PMID: 27280386). Conserved and redundant roles of 
VPS13 proteins in mitochondria function underscore the 
dependence of these organelles, which are excluded from 
membrane traffic, on protein mediated lipid exchange 
with other membranes. The two other mammalian 
VPS13 isoforms, VPS13B and VPS13C, have a different 
subcellular localization, with VPS13C, whose mutations 
result in Parkinson’s disease,1 acting at contacts between 
the ER and late-endosomes/lysosomes. In my talk, I 
will summarize these studies and discuss how these 
discoveries shed light on mechanisms of disease, with 
emphasis on Chorea Acanthocytosis.
Kumar, Leonzino … Reinisch & De Camilli, JCB, 2018
PeiQi … & Reinisch, JCB, 2020
Guillén-Samander, Leonzino … & De Camilli, BioRxiv 2020
Vps13 is associated with multiple 
organelles and is required for timely 
removal of bulky cellular remnants
Ody C.M. Sibon1
1. Department of Biomedical Sciences of Cells and 
Structures, University Medical Center Groningen, University 
of Groningen, The Netherlands.
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Abstract
The evolutionary conserved VPS13A gene is associated with 
the neurodegenerative disorder Chorea Acanthocytosis. 
We demonstrated that VPS13A is a peripheral membrane 
protein, associated with mitochondria, the endoplasmic 
reticulum, and lipid droplets. VPS13A is localized at sites 
where the endoplasmic reticulum and mitochondria are in 
close contact. VPS13A interacts with the ER residing protein 
VAP-A via its FFAT domain. Interaction with mitochondria 
is mediated via its C-terminal domain. In VPS13A-depleted 
cells, ER and mitochondria contact sites are decreased, 
mitochondria are fragmented and mitophagy is decreased. 
VPS13A also localizes to lipid droplets and affects lipid 
droplet motility. We further explored possible cellular 
functions of VPS13A using Drosophila melanogaster 
with its large cells and versatile genetic tools as a model 
organism. We demonstrated the presence of increased 
numbers of lipid droplets in specific brain areas of Vps13 
mutants. We also demonstrated that Drosophila Vps13 
is required for timely removal of large cellular remnants. 
During this process a Vps13-rich and Vps13-dependent 
membranous structure is being formed that surrounds the 
to-be-degraded cellular remnants. We will discuss how 
these new data link impairment of Vps13-related proteins 
with neurodegeneration.
The role of VPS13A in endolysosomal 
and autophagic pathways: a CRISPR/
Cas9-based cellular model of ChAc for 
phenotype-based compound screening 
Alba Tornero-Écija1, María-Ángeles Navas2, Olivier Vincent1 
and Ricardo Escalante1
1. Instituto de Investigaciones Biomédicas Alberto Sols; 
C.S.I.C./U.A.M.; Madrid, Spain.
2. Universidad Complutense de Madrid. Spain.
Abstract
VPS13A is a lipid transfer protein that localizes to different 
membrane contact sites between organelles and its 
mutation causes the rare disease chorea-acanthocytosis 
(ChAc). Previous work from our laboratory demonstrated 
that VPS13A localizes at the interface between 
mitochondria-endoplasmic reticulum and between 
mitochondria-endosomes in HeLa cells. Inhibition of 
VPS13A expression by siRNAs results in defects in lysosome 
function and accumulation of endolysosomal markers such 
as RAB7A and LAMP1 (Muñoz-Braceras, S; Tornero-Écija, 
AR; Vincent, O and Escalante, R. (2019). VPS13A is closely 
associated with mitochondria and is required for efficient 
lysosomal degradation. Dis Model Mech. 12(2)(PMID: 
30709847). Accumulation of endolysosomal markers 
could be a useful phenotype for testing compounds in 
preclinical studies. However, the high cellular variability 
intrinsically linked to the use of siRNAs prevented us 
from obtaining conclusive results. We have optimized 
a CRISPR/Cas9 approach to generate a reliable model to 
compare wild-type and VPS13A Knock-out HeLa cells. The 
characterization of this model and preliminary results will 
be presented.
Towards understanding the function of 
VPS13B in vesicular trafficking through 
the study of spermiogenesis
Romain Da Costa1,2*, Morgane Bordessoules1,2, Magali 
Guilleman3, Virginie Carmignac1,4, Hortense Courot1, 
Amandine Bataille5, Amandine Chlémaire5, Céline Bruno1,3, 
Patricia Fauque1,3, Christel Thauvin1,2,6, Laurence Faivre1,2,7 
and Laurence Duplomb1,2
1. Inserm, UMR1231, Equipe GAD, Université de Bourgogne 
Franche Comté, F-21000 Dijon, France.
2. FHU TRANSLAD, CHU Dijon, F-21000 Dijon, France.
3. Laboratoire de Biologie de la Reproduction, Hôpital 
François Mitterrand, Université de Bourgogne, F-21000 
Dijon, France.
4. Centre de Référence Maladies Génétique à Expression 
Cutanée MAGEC-Mosaique, CHU Dijon, Dijon France.
5. Plateforme d’Imagerie Cellulaire CellImaP/DimaCell, 
Inserm LNC UMR1231, F-21000 Dijon, France.
6. Centre de Référence Déficiences Intellectuelles de 
Causes Rares, CHU Dijon, F-21000 Dijon, France.
7. Centre de Référence Anomalies du Développement 




Cohen syndrome (CS) is a rare genetic disorder caused by 
variations affecting the VPS13B gene. It is characterized 
by a wide variety of clinical features that includes a typical 
facial dysmorphism, hypotonia, neutropenia, microcephaly, 
intellectual disability, and severe visual impairments. 
Understanding the molecular function of VPS13B is a 
prerequisite to the development of therapeutic approaches 
to treat chronic and progressive symptoms of CS. So far, 
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very little is known about VPS13B cellular functions. Based 
on its domain structure and homologies with the yeast 
VPS13, VPS13B is likely to play a role in vesicle-mediated 
sorting and transport of proteins. To study these functions, 
we produced the Vps13b∆Ex3/∆Ex3 mouse model. Initial 
phenotyping of the line revealed that male mutant mice 
were infertile due to morphologically abnormal, non-
motile and short-lived spermatozoa. Histological analysis 
of the spermiogenesis showed that Vps13b∆Ex3/∆Ex3 
spermatids were unable to produce an acrosome, the large 
nuclear-capping vesicle that contains the hydrolases and 
other components allowing the sperm nucleus entry into 
the oocyte. In accordance with previous reports on patient 
fibroblasts we found that the Golgi apparatus was affected 
in Vps13b∆Ex3/∆Ex3 spermatids. It lacked the ability to 
orientate towards the nucleus and surround the nuclear 
membrane. In addition, marking Golgi-derived vesicles 
with a lectin (PNA) revealed that instead of being targeted 
to the nuclear membrane those vesicles were targeted to 
the early endosome of early spermatids. As spermatids 
matured, acrosomal vesicles were found enclosed and 
degraded in lysosomal structures. Altogether, our study 
shows that Vps13b is an acrosomal membrane protein 
that redirects Golgi-derived vesicles towards the nuclear 
membrane. We now investigate whether VPS13B is also 
an addressing factor for other subsets of vesicles in CS-
affected tissues and try to identify the compartments it 
targets.
Functional insights from structural studies 
of VPS13’s and related proteins
Karin M. Reinisch1
1. Department of Cell Biology, Yale School of Medicine, 333 
Cedar Street, New Haven, CT, 06520, USA.
Abstract
Insights as to VPS13 function from structural and 
biochemical studies will be discussed. We found that 
VPS13 and related proteins may form bridges between 
membranes of organelles apposed at so-called contact sites 
that allow for bulk transfer of lipids between them. In this 
model, VPS13 proteins transfer lipids between the cytosolic 
leaflets of these membranes. In order to avoid bilayer 
asymmetry as lipids are depleted or augmented in just one 
of the leaflets of the donor and acceptor membrane, VPS13 
proteins likely cooperate with scramblases that equilibrate 
lipids between bilayer leaflets. 
VPS13 PROTEINS IN HEALTH AND DISEASE
Using human disease mutations to dissect 
the functions of yeast Vps13
Jae-Sook Park1 and Aaron M. Neiman1




The large size of the Vps13 protein makes screening for 
functionally significant missense mutations difficult. 
Missense alleles identified by sequencing of patients with 
VPS13-related diseases in humans, therefore, provide a 
valuable resource to explore structure-function relationships 
of this protein family. We have introduced mutations in the 
yeast VPS13 based on alleles found in chorea-acanthocytosis 
(VPS13A), Cohen syndrome (VPS13B), FTLD (VPS13C), and 
cerebellar ataxia (VPS13D) patients. Collectively, these 
mutations occur in different domains across the protein.
Alleles from chorea-acanthocytosis and cerebellar 
ataxia patients create distinct separation-of-function 
phenotypes that can be linked to changes in the steady-
state distribution of the protein. The combination of either 
of these alleles with a second, intragenic mutation in 
VPS13 restores localization and suppresses the mutant 
phenotypes.  The implications of this genetic interaction for 
the regulation of yeast Vps13 will be discussed.
Vps13 protein and calcium signaling in yeast
Joanna Kaminska1, Piotr Soczewka1, Damian Kolakowski1, 
Patrycja Wardaszka1 and Teresa Zoladek1
1. Dept. of Biochemistry and Cell Biology, Stony Brook 
University, USA
Abstract
Vps13 are lipid transfer proteins localized in several 
membrane contact sites, such as nuclear-vacuolar 
junctions and endosome-mitochondrial junctions. 
Defects in Vps13(A-D) proteins in humans result in a rare 
neurodegenerative disease of unknown pathogenesis for 
which there is no cure. Yeast is a good model system to 
study function and regulation of Vps13 proteins, the effect 
of human mutations on cell physiology and to screen for 
genetic and chemical suppressors of vps13 mutations. In 
yeast, there is a unique VPS13 gene and its deletion, vps13∆, 
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impairs intracellular trafficking and the actin cytoskeleton, 
and renders cells hypersensitive to various stress conditions, 
including sodium dodecyl sulphate (SDS) stress. Using this 
phenotype we found that vps13 is suppressed by expression 
of MYO3 fragment encoding N-terminus of myosin which 
binds calmodulin, RCN2 encoding a negative regulator of 
calcineurin, a calcium-dependent phosphatase, PMC1 gene 
for vacuolar calcium transporter, and mutant gene encoding 
calmodulin. We also found that calcium signaling is 
increased and calcineurin is hyperactivated in vps13 mutant. 
Importantly, ethylene glycol tetraacetic acid (EGTA), which 
sequesters calcium, and FK506 inhibitor of calcineurin were 
found to be suppressors of vps13 growth defect, pointing to 
the possible target for chemical intervention in VPS13-related 
diseases. Furthermore, we found that APT1 domains from 
yeast Vps13 and human Vps13A bind specific phospholipids 
and this binding is calcium-dependent. Pathogenic mutation 
in APT1 domain of Vps13A diminished phospholipid binding 
and changed its regulation. This supports the view that 
calcium regulation is also important for functioning of Vps13 
proteins and in pathogenesis of VPS13-related diseases. This 
study was financed by the National Science Centre, Poland 
(UMO-2015/19/B/NZ3/01515).
Therapeutic Targeting of Lyn Kinase To 
Treat ChoreaAcanthocytosis: evidence 
from pre-clinical studies
Kevin Peikert1,19†, Enrica Federti†2, Alessandro Matte’2, 
Gabriela Constantin2, Enrica Caterina Pietronigro2, Paolo 
Francesco Fabene3, Paola Defilippi4, Emilia Turco4, Federico 
Del Gallo3, Piero Pucci5,21, Angela Amoresano5, Anna Illiano5, 
Flora Cozzolino5,21, Maria Monti5,21, Francesca Garello6, 
Enzo Terreno6, Seth L. Alper7, Hannes Glaß1, Lisann Pelzl8,9, 
Katja Akgün10, Tjalf Ziemssen10, Rainer Ordemann11, 
Florian Lang8, Anna Maria Brunati12, Elena Tibaldi12, 
Immacolata Andolfo13, Achille Iolascon13, Mario Buffelli3, 
Carlo Zancanaro3, Erika Lorenzetto3, Angela Siciliano2, 
Massimiliano Bonifacio2, Adrian Danek15, Ruth H Walker16,17, 
Andreas Hermann1,18,19,18,20‡* and Lucia De Franceschi2‡
1. Translational Neurodegeneration Section “Albrecht-
Kossel”, Department of Neurology, University Medical 
Center Rostock, University of Rostock, Rostock, Germany.
2. Department of Medicine, University of Verona; Verona; 
Italy.
3. Dept of Neuroscience, Biomedicine and Movement 
Sciences, University of Verona; Verona; Italy.
4. Department of Biotecnologie Molecolari e Scienze per la 
Salute, University of Torino; Italy.
5. Dept of Chemical Sciences, University Federico II of 
Napoli, Napoli; Italy.
6. Molecular Imaging Center – Dept. of Molecular 
Biotechnology and Health Sciences, University of Torino; 
Italy.
7. Division of Nephrology, Beth Israel Deaconess Medical 
Center, Harvard Medical School, Boston (MA), USA.
8. Department of Physiology I, Eberhard Karl University, 
Tübingen, Germany.
9. Transfusion Medicine, Eberhard Karl University, Tübingen, 
Germany.
10 Department of Neurology, University Hospital Carl 
Gustav Carus, Technische Universität Dresden, Dresden, 
Germany.
11. Medical Department I, University Hospital Carl Gustav 
Carus, Technische Universität Dresden, Dresden, Germany.
12. Dept of Molecular Medicine, University of Padua, Padua, 
Italy.
13. Dept. of Molecular Medicine and Medical Biotechnology; 
University of Naples Federico II, Naples, Italy.
14. Department of Neurology, James J. Peters Veterans 
Affairs Medical Center, Bronx (NY) USA.
15. Department of Neurology, Ludwig Maximilians 
University of Munich; Munich; Germany.
16. Department of Neurology, Icahn School of Medicine at 
Mount Sinai, New York, USA.
17. DZNE, German Center for Neurodegenerative Diseases, 
Research Site Dresden and Rostock/Greifswald, Germany.
18. Center for Transdisciplinary Neurosciences Rostock 
(CTNR), University Medical Center Rostock, University of 
Rostock, Rostock, Germany.
19. Division for Neurodegenerative Diseases, Department 
of Neurology, Technische Universität Dresden, Dresden, 
Germany.
20. Center for Regenerative Therapies Dresden, Dresden; 
Germany.
21. CEINGE Biotecnologie Avanzate, Naples, Italy.
Abstract
Chorea-Acanthocytosis (ChAc) is a devastating, little 
understood, and currently untreatable neurodegenerative 
disease caused by VPS13A mutations. Based on our 
recent demonstration that accumulation of activated 
Lyn tyrosine kinase is a key pathophysiological event in 
human ChAc cells, we took advantage of Vps13a-/- mice, 
which phenocopied human ChAc. Vps13a-/- mice display 
(i) acanthocytes; (ii) signs of both hyper- and hypokinetic 
movement disorders; (iii) accumulation of active Lyn 
and of autophagy-related proteins in RBCs; and (iv) 
RBC retention of remnants of double1 membrane and 
multivesicular bodies. In isolated basal ganglia of Vps13a-/- 
mice, we found signs of neurodegeneration associated 
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with (i) accumulation of Lyn, stabilized in high molecular 
weight complexes; (ii) accumulation of autophagy related 
proteins; and (iii) reduction in expression of beclin-1, a key 
initiator of autophagy, due to increased caspase 3 activity. 
Noteworthy, we also found neuroinflammation in Vps13a-/- 
mice associated with activation of NF-kB p65 and increased 
expression of IL-1b further emphasizing similarities between 
ChAc and other neurodegenerative disorders characterized 
by abnormal proteostasis such as PD or AD. Normalization 
of phenotypes in the Vps13a-/- Lyn-/- double knock out 
model substantiates the central role of accumulation of 
active Lyn in the pathophysiology of ChAc. Using proteomic 
approach, we found accumulation of, alpha-synuclein and 
phospho-tau proteins in Vps13a-/- basal ganglia secondary 
to impaired autophagy leading to neuroinflammation. Mice 
double knockout Vps13a-/- Lyn-/- showed normalization 
of red cell morphology and improvement of autophagy 
in basal ganglia. We then in vivo tested pharmacologic 
inhibitors of Lyn: Dasatinib and Nilotinib. Dasatinib failed 
to cross the mouse brain blood barrier (BBB), but the 
more specific Lyn kinase inhibitor nilotinib, crosses the 
BBB. Nilotinib ameliorates both Vps13a-/- hematological 
and neurological phenotypes, improving autophagy and 
preventing neuroinflammation. Our data support the 
repurposing of nilotinib as new therapeutic option for ChAc 
patients to be tested in phase II clinical trial.
VPS13A distribution in the mouse basal 
ganglia 
Esther García-García1,2,3, Albert Coll-Manzano1,2,3, Maria 
Carreras-Caballé1,2,3, Nerea Chaparro-Cabanillas1,2,3, Mercè 
Masana1,2,3, Jordi Alberch1,2,3 and Manuel J. Rodríguez1,2,3
1. Dept. Biomedical Sciences, Institute of Neurosciences, 
School of Medicine and Health Sciences, Universitat de 
Barcelona, Barcelona, Spain
2. Institut d’Investigacions Biomèdiques August Pi i Sunyer 
(IDIBAPS), Barcelona, Spain
3. Centro de Investigación Biomédica en Red sobre 
Enfermedades Neurodegenerativas (CIBERNED), Madrid, 
Spain.
Abstract
Chorea-acanthocytosis (ChAc) is caused by a VPS13A 
gene mutation leading to marked reduction or absence 
of VPS13A protein. ChAc patients show progressive 
movement disorders such as chorea, dystonia, 
parkinsonism and involuntary oral biting, among others. 
Since progressive impairment of basal ganglia circuitry 
underlie the appearance of movement disorders, it has 
been proposed that dysfunction of basal ganglia may 
account for ChAc pathophysiology. Actually, one of the 
main neuropathologic features in VPS13A mutations is a 
selective degeneration of the brain striatum. Because of 
that, a complete characterization of both VPS13A function 
and ChAc neuropathology in the brain and specifically 
in striatal neurons is needed. However, there is a poor 
knowledge about the VPS13A expression in the brain. 
We analyzed the VPS13A distribution in the mouse basal 
ganglia and related nuclei. We found a widespread VPS13A 
distribution along basal ganglia, with low expression levels 
in the striatum. By contrast we found higher VPS13A 
expression in the cortex. Thalamic nuclei and substantia 
nigra presented moderate VPS13A expression. VPS13A 
was present in glutamatergic pyramidal neurons, but 
also in some GABAergic neurons. At the subcellular level 
VPS13A was located in the soma and neurites, interacting 
with both the endoplasmic reticulum and mitochondria. 
However, we found no VPS13A within the dendritic spines 
by immunocytochemistry, which is consistent with the 
presence but not enrichment of VPS13A we found in 
cortical synaptosomes. These results indicate that VPS13A 
has not a direct role in synaptic transmission. However, 
the relatively low VPS13A expression in the striatum 
appears to be related with the specific vulnerability of this 
nucleus to ChAc. Thus, characterization of the molecular 
and cellular basis of this selective striatal cell loss should 
report significant progress toward the knowledge of ChAc 
pathophysiology.
Supported by SAF2017-88076-R, Ministerio de Ciencia, 
Innovación y Universidades, and Fundación ChAc.
Chorein maintains mitochondrial 
morphology in mouse sperm and interacts 
with mitochondrial enzyme IDH3A
Kaoru Arai1, Omi Nagata1, Hitoshi Sakimoto1, Akira Sano1 
and Masayuki Nakamura1
1. Department of Psychiatry, Kagoshima University 
Graduate School of Medical and Dental Sciences, 8-35-1 
Sakuragaoka, Kagoshima, 890–8520, Japan
Abstract
ChAc model mice, which have a homozygous deletion of 
exons 60–61 in Vps13a, exhibited male infertility. They 
showed no significant differences from wild types in terms 
of sperm count, or sexual activity. They showed severely 
diminished sperm motility.
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Immunocytochemical study revealed that chorein 
immunoreactivity is detected only in the mid-piece, 
mitochondria-rich region, of the sperm of wild type mice. 
Electron microscopy revealed abnormal ultrastructural 
morphology of the mitochondria in the mid-piece 
of sperm from ChAc model mice. The morphological 
abnormalities were seemed to occur at late stage 
of mitochondrial sheath developmental process in 
spermatogenesis. These results suggest that chorein 
is essential in mouse sperm for the arrangement of 
mitochondria and sperm motility. In addition, we 
identified isocitrate dehydrogenase 3 alpha sub unit 
(IDH3A), a mitochondrial tricarboxylic acid cycle enzyme 
as a chorein-interacting protein using proteomics 
analysis following co-immunoprecipitation (co-IP) of 
mouse sperm. Chorein-1DH3A interaction was also 
detected in both mouse striatum and Human Embryonic 
Kidney cells. Western blotting analysis revealed the 
reduction of immunoreactivities of the IDH3A in ChAc 
model mouse sperm. Although the relationship between 
IDH3A reduction and morphological abnormalities of 
mitochondria in ChAc model mouse remains unclear, it 
was suggested that chorein, mitochondrial morphology 
and IDH3A are involved in ChAc pathophysiology.
PRESENT AND FUTURE CLINICAL CARE 
OF NEUROACANTHOCYTOSIS
Old and novel clinical and paraclinical 
markers of Chorea acanthocytosis
Andreas Hermann1,2,3
1. Translational Neurodegeneration Section “Albrecht-
Kossel”, Department of Neurology, University Medical 
Center Rostock, University of Rostock, Rostock, Germany. 
2. DZNE, German Center for Neurodegenerative Diseases, 
Research Site Rostock/Greifswald, Rostock, Germany. 
3. Center for Transdisciplinary Neurosciences Rostock 
(CTNR), University Medical Center Rostock, University of 
Rostock, Rostock, Germany.
Abstract
Chorea-Acanthocytosis (ChAc) is an ultra-rare 
neurodegenerative disease caused by mutations in 
the VPS13A gene. It is characterized by a spectrum 
of neurological symptoms (e.g., chorea, epilepsy, 
parkinsonism, cognitive decline or neuro-/myopathy) and 
acanthocytosis. It is thus not only a typical differential of 
Huntington’s disease, but also for other disease conditions. 
Thus, markers which help in the diagnostics of ChAc would 
be helpful. Furthermore, both pathognomonic markers and 
markers for clinical progression are of urgent need in case 
one want to perform clinical trials.
Even though possibly representing with a plethora of 
clinical phenotypes, there are some which clearly direct us 
to ChAc. E.g. clinical symptoms such as orolingual biting, 
tongue protrusions and loss of deep tendon reflexes are 
typically found in ChAc. Blood cell acanthocytosis clearly 
helps diagnosing ChAc, but also unexplained and persistent 
CK elevation independent from activity or seizures in the 
context of a movement disorder should make us think of 
ChAc. Of note, however, there is surprisingly little known 
about the longitudinal behavior during the disease course 
of all of these clinical and paraclinical “biomarkers” and 
thus their strength as potential read-outs parameters for 
disease modifying actions remains elusive.
The talk will give insights in classical and novel potential 
markers of ChAc. Limited knowledge on the natural history 
of ChAc remains a barrier for “clinical trial readiness”.
Outcome of deep brain stimulation in two 
patients with chorea-acanthocytosis
Berta Pascual-Sedano1,2,3, J Pérez-Pérez1, L Rebordão4, C 
García-Sánchez1,3, I Aracil1,2,3, A Campolongo1,2,3, A Gironell1,3, 
R Rodriguez-Rodríguez5, MJ Álvarez- Holzapfel5, B Gómez- 
Ansón6, V Medina6, J Pagonabarraga1,2 and J Kulisevsky1,2,3
1. Movement Disorders Unit, Neurology department, 
Hospital de la Santa Creu I Sant Pau, Barcelona, Spain.
2. Faculty of Health Sciences, Universitat Oberta de 
Catalunya (UOC), Barcelona, Spain.
3. Center for Networked Biomedical Research in 
Neurodegenerative Diseases (CIBERNED), Instituto de 
Salud Carlos III, Madrid, Spain.
4. Department of Neurology, Hospital Professor Doutor 
Fernando Fonseca, Amadora, Portugal.
5. Neurosurgery Departament, Hospital de la Santa Creu i 
Sant Pau, Barcelona, Spain.
6. Neuroradiology, Hospital de la Santa Creu i Sant Pau, 
Barcelona, Spain.
Abstract
Chorea-acanthocytosis is an autosomal recessive very 
disabling disease characterized by multiorgan involvement, 
including central and peripheral nervous system. The 
available treatment is symptomatic. We present the 
outcome of two patients who underwent deep brain 
stimulation (DBS).
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CASE REPORTS
Case 1: A 30-year-old man with familiar history of bipolar 
disease and consanguinity, presented with seizures at 25 
years old. One year later, progressive orofacial movements 
and vocalizations appeared. After that, he started with 
lingual mutilation, weight loss and behavior problems. He 
showed inattention, impulsivity, vocalizations, dysarthria, 
sialorrhea, feeding dystonia, generalized chorea, 
bradykinesia and instability with freezing. Genetic test was 
positive for chorea-acanthocytosis. He became partially 
dependent, with severe sleeping and eating impairment. 
UHDRS-TMS 51/124, UHDRS-FCS 8/13, UHDRS-IS 50%. 
Pallidal DBS was performed. Three months1 post-DBs he 
had a marked improvement of attention, gait, swallowing, 
weight and chorea, becoming almost independent 
(UHDRS-TMS 14/124, UHDRS-FCS 20/33, UHDRS-IS 70%). At 
14 months post-surgery the improvement was maintained.
Case 2: 43-year-old man with chorea-acanthocytosis 
started at 21 years-old (biting the lower lip). He later 
suffered of progressive motor and behavioral involvement. 
Blood test confirmed acanthocytes, and corein was positive 
in red blood cells. Due to severe feeding dystonia, PEG was 
needed for enteral feeding. Over time, choreo-ballism 
prevented him from walking and even sitting due to falls, 
and he had serious lip mutilation, vocalizations, anxiety, 
disinhibition, lack of judgment and obsessions. Scores pre-
DBS: UHDRS-TMS 52/124, UHDRS-FCS 5/13. Pallidal DBS was 
performed and just after DBS-activation he had a marked 
improvement, especially on feeding dystonia (he no longer 
uses PEG), choreo-ballism (reducing falls and allowing 
sitting) and behavior; this improvement is maintained 5 
months post-DBS. However, a freezing of gait has appeared.
Conclusion: Functional surgery can be useful to improve 
motor and behavioral symptoms in patients with 
chorea-acanthocytosis; however, the eligibility should be 
individualized considering the benefit-risk profile.
Targeting Lyn kinase and PI3K pathway –  
Potential therapies for chorea-
acanthocytosis in the future?
Kevin Peikert1,2, Hannes Glaß1,2, Alessandro Matte3, Enrica 
Federti3, Lisann Pelzl4,5, Katja Akgün2, Tjalf Ziemssen2, 
Rainer Ordemann6, Florian Lang4, Lucia De Franceschi3 and 
Andreas Hermann1,2,7–9
1. Translational Neurodegeneration Section “Albrecht-
Kossel”, Department of Neurology, University Medical 
Center Rostock, University of Rostock, Rostock, Germany. 
2. Department of Neurology, University Hospital Carl 
Gustav Carus, Technische Universität Dresden, Dresden, 
Germany. 
3. Department of Medicine, University of Verona, Verona, 
Italy. 
4. Department of Physiology I, University of Tübingen, 
Tübingen, Germany. 
5. Transfusion Medicine, Medical Faculty, Eberhard Karl 
University, Tübingen, Germany.
6. Medical Department I, University Hospital Carl Gustav 
Carus, Technische Universität Dresden, Dresden, Germany. 
7. Center for Regenerative Therapies Dresden (CRTD), 
Technische Universität Dresden, Dresden, Germany. 
8. DZNE, German Center for Neurodegenerative Diseases, 
Research Site Rostock/Greifswald, Rostock, Germany. 
9. Center for Transdisciplinary Neurosciences Rostock 
(CTNR), University Medical Center Rostock, University of 
Rostock, Rostock, Germany.
Abstract
Chorea-Acanthocytosis (ChAc) is an ultra-rare 
neurodegenerative disease caused by mutations in 
the VPS13A gene. It is characterized by a spectrum of 
neurological symptoms (e.g., chorea, epilepsy, cognitive 
decline or myopathy) and acanthocytosis. Elevated 
Lyn kinase activity and altered PI3K signaling has been 
identified as key pathophysiological mechanisms. They 
represent promising “druggable” targets for a potential 
disease-modifying therapy.
We evaluated an individual off-label treatment with the 
FDA-approved Lyn kinase inhibitor Dasatinib in three ChAc 
patients. Alongside with a thorough safety monitoring, 
we assessed clinical (e.g. UPDRS, UHDRS, Quality of Life) 
as well as paraclinical and experimental parameters (e.g. 
acanthocyte and creatine kinase level, Lyn kinase activity, 
actin cytoskeleton in red blood cells).
Dasatinib treatment was safe in all three patients. 
Only mild side effects occurred. The clinical parameters 
remained stable without significant improvement or 
deterioration. Regain of deep tendon reflexes was observed 
in one patient. Reduction of elevated Lyn kinase activity 
and autophagy markers as well as restoration of actin 
cytoskeleton was found in red blood cells.
In summary, the experimental read-outs point to 
target engagement in the red blood cells. However, effects 
on the central nervous system could not be shown within 
a rather short duration of treatment with the predefined 
read-outs. 
We furthermore discuss the rationale and perspectives 
of Lithium treatment modifying downstream effects of 
altered PI3K signaling in ChAc.
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Neuroacanthocytosis case registry: 
current status and future goals
Adrian Danek1, Benedikt Bader1,2, Gabriel Miltenberger-
Miltenyi1,3, Kevin Peikert4, Bernhard Landwehrmeyer5, 
Glenn† and Ginger Irvine6
1. Neurologische Klinik und Poliklinik, Ludwig-Maximilians-
Universität München, Germany.
2. Schön Klinik Bad Aibling, Fachklinik für Neurologie, Bad 
Aibling, Germany.
3. Instituto de Medicina Molecular, Faculdade de Medicina 
da Universidade de Lisboa, Portugal.
4. Klinik und Poliklinik für Neurologie, Universitätsmedizin 
Rostock, Germany.
5. Klinik für Neurologie, Universitätsklinikum Ulm, Germany.
6. Advocacy for Neuroacanthocytosis Patients, London, UK.
Abstract
Establishing a case registry was discussed from the very 
first symposium in 2002 to define the natural history of 
neuroacanthocytosis syndromes and to serve as recruitment 
tool for future therapeutic trials. Set up as a submodule of 
the European Huntington’s Disease Network (www.euro-
hd.net/html/na/registry), it offers room for an extensive set 
of patient information. First data were deposited in 2008 
and 50+ cases overall were entered. The registry was most 
active while part of the first EMINA consortium yet has been 
dormant since. It is a pressing need to revive the registry 
effort and to tackle open questions. Originally conceived 
for all “neurocanthocytosis” syndromes, it appears more 
appropriate to include only cases of chorea-acanthocytosis 
and of McLeod syndrome, both only with biologically 
confirmed diagnoses. Ethical and data protection issues 
must be re-analysed and amended accordingly. Consent 
forms so far were available only in English. Data monitoring 
and quality control must be implemented. In addition to 
clinical data there must be an opportunity to collect imaging 
data such as from MRI, but also data from wearables and 
other aspects of “e-health” are of interest. Data-entering 
colleagues had willingly collaborated but the motivation 
of busy clinicians must be improved. One possible incentive 
may be the free diagnostic information (chorein Western 
blot service) made available by the patient advocacy but also 
direct financial reimbursement could be considered. Case 
acquisition might be further improved trough a mechanism 
for self-registration by patients. Continuous contact and 
communication will be essential to obtain follow-up data.
The questions of data ownership, data sharing and of 
publication policies deserve serious effort.
Finally, to secure continuity after 2023 we plan a gradual 
transition of responsibility from the Munich to the Rostock 
group.
GLENN IRVINE PRIZE AWARDEE
XK is a partner for VPS13A: A molecular 
link between Chorea Acanthocytosis and 
McLeod syndrome
Jae-Sook Park1 and Aaron M. Neiman1
1. Dept. of Biochemistry and Cell Biology, Stony Brook 
University, USA
Abstract
Vps13 is a highly conserved lipid transfer protein found at 
multiple inter-organelle membrane contact sites.  In yeast, 
the single Vps13 protein is recruited to different contact 
sites through interaction with different adaptor proteins. 
Mutations in human VPS13A cause the neurodegenerative 
disease Chorea Acanthocytosis (ChAc).  The symptoms 
of ChAc resemble those of McLeod syndrome caused by 
mutations in the XK gene.  These observations suggest 
that XK could be a partner protein for VPS13A.  We report 
that XK forms a complex with VPS13A in human cells, and 
XK overexpression relocalizes VPS13A from lipid droplets 
to subdomains of endoplasmic reticulum (ER).  A VPS13A 
protein carrying the ChAc-linked mutation (W2460R) in 
the VPS13 adaptor binding (VAB) domain failed to localize 
to lipid droplets and did not relocalize to ER subdomains 
upon XK overexpression.  These observations suggest that 
the function of VAB domain in regulating VPS13 localization 
might be conserved in human VPS13A and that disruption 
of a VPS13A-XK complex is the common basis for ChAc and 
McLeod syndrome.
FOCUS IS ON PATIENTS, WITH CAREGIVERS 
PRESENT
Impact of Neuroacanthocytosis syndromes 
on speech and swallowing function 
E. Tripoliti1,2
1. Institute of Neurology, Unit of Functional Neurosurgery, 
UCL, London UK
2. National Hospital for Neurology and Neurosurgery, UCLH, 
NHS Trust, London UK.
Abstract
Aim: The aim of the talk was to describe the variability 
of speech and swallowing presentation in patients with 
NA syndromes and to discuss treatment options for 
behavioural therapies.
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Background: Speech and communication can be affected 
at every stage of the disease process, and dysarthria can 
be one of the earlier symptoms of the disease. Similarly 
maintaining the safety and pleasure from eating and 
drinking with family is part of our quality of life. 
Methods: A combination of anecdotal evidence from short 
reports and clinical experience shows the wide spectrum and 
the changes of presentation, from hyperkinetic (too much 
movement) to hypokinetic (too little). Symptoms affecting 
speech involve choreic movements of the trunk and the 
limbs, oro-facio-lingual dyskinesias, limb or facial dystonias, 
and difficulty initiating movement, with reduced amplitude. 
Factors contributing to the variability of presentation are age 
of onset (young adult or middle aged), other treatments 
(surgical, BOTOX, pharmacological), effect of stress and 
fatigue, and availability of multidisciplinary team input. 
Results: The aim of any speech and swallowing intervention 
is to maintain communication and participation for as long 
as possible. A variety of speech approaches can be deployed, 
depending on the stage and the particular symptoms. Sensory 
tricks can help and need to be acknowledged and expanded. 
Mouth guards can be useful for tongue dystonia but can 
impair speech. BOTOX and other pharmacological effects 
should be monitored for their effects on function before and 
after their initiation. Working on louder voice can improve not 
just voice, but articulation clarity. Singing is always beneficial 
for both the voice and the soul. Voice banking and Alternative 
communication systems will be discussed.
Swallowing can be affected in the oral stage by the 
uncontrolled movements of the tongue and the reduced 
lip seal. Pharyngeal stage can preserve the safety of 
swallowing. Patients should be encouraged to sit more 
upright if possible and to minimize distractions during meals. 
Training the expiratory muscles (with e.g. the EMST150) can 
help with the cough strength and clearing of saliva.
Conclusion: Maintaining communication and swallowing 
function for as long as possible is paramount. Balancing the 
hypo-and hyper-kinetic symptoms throughout the disease 
process requires flexibility and further knowledge, through 
more longitudinal studies.
POSTER # 1
Detection of PANK2 mutations in the 
“B siblings” whose Y2721C VPS13A 
lacks effects in cell models
Adrian Danek1, Jae-Sook Park2, Aaron Neiman2, Antonio 
Velayos-Baeza3, Gabriel Miltenberger-Miltenyi1,4, Matias 
Wagner5, Bettina Schmid6, Alexander Hruscha6, Qing 
Wang1,6,7, Richard Hardie8, Sonia Gandhi9 and Ginger Irvine10
1. Neurologische Klinik und Poliklinik, Ludwig-Maximilians-
Universität München, Germany.
2. State University of New York at Stony Brook, NY, USA.
3. Dept. of Physiology, Anatomy and Genetics/Wellcome 
Centre for Human Genetics University of Oxford, 
UK.
4. Instituto de Medicina Molecular, Faculdade de Medicina 
da Universidade de Lisboa, Portugal.
5. Technische Universität München, Germany.
6. Deutsches Zentrum für Neurodegenerative Erkrankungen, 
Munich, Germany.
7. Graduate School for Systemic Neuroscience, Ludwig-
Maximilians-Universität München, Germany.
8. Institute of Clinical Neurosciences, University of Bristol, 
UK.
9. National Hospital for Neurology and Neurosurgery, 
London, UK.
10. Advocacy for Neuroacanthocytosis Patients, London, 
UK.
Abstract
A sister and brother, aged 56 and 55, had been diagnosed 
with neuroacanthocytosis in their twenties, based 
on childhoodonset behavioural as well as movement 
abnormalities and on 15% acanthocytes (Hardie et al. 
1991). Findings in the parents and family history were 
unremarkable. The original genetic work-up of chorea-
acanthocytosis (ChAc) showed chromosome 9 linkage 
also in this “CHAC9” pedigree (Rubio et al. 1997). When the 
responsible gene (CHAC, later renamed as VPS13A) was 
identified (Rampoldi et al. 2001), a single heterozygous 
missense mutation (c.8162A>G, Y2721C) was found in 
this family. The siblings’ clinical findings were, however, 
exceptional because of their onset age, normal reflexes 
and normal CK levels. Their mutation, along with missense 
mutations VPS13A L67P, I90K, A1095P, and I2771R was 
modelled in yeast (Park et al. 2016; Rzepnikowska et al. 
2017). Among the cognate mutations (Vps13 L66P, C89K, 
L1107P, Y2702C, and I2749R) only Y2702C, corresponding 
to the CHAC9 mutation, failed to show a phenotype in yeast. 
In human-derived cells (HEK293T) we found the Y2721C 
mutant protein localizes like wild-type VPS13A protein. The 
siblings were thought lost to follow-up but after seeking 
contact with the Advocacy for Neuroacanthocytosis 
Patients they agreed to further analyses. Erythrocyte 
membrane Western blot showed a normally expressed 
VPS13A protein (chorein) band. Exome sequencing, 
confirming the c.8162A>G mutation, failed to find any 
other VPS13A mutations, yet detected heterozygous 
mutations in PANK2 (NM_024960.4): c.101T>A, F34Y and 
c.688G>A, G230R. We conclude that Y2721C is a benign 
VPS13A polymorphism and that the neuroacanthocytosis 
umbrella diagnosis in the siblings must be refined into 
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pantothenate kinase associated neurodegeneration. 
These observations show that a diagnosis of ChAc must 
ideally be confirmed by reduced chorein expression and/or 
by proof of clearly pathogenic mutations in both VPS13A 
alleles. Mere presence of a single mutation with unclear 
functional effects is clearly insufficient to support the 
diagnosis
POSTER # 2
Characterization of the distribution and 
localization of VPS13A in the mouse brain 
to understand the pathophysiology of 
chorea-acanthocytosis
Esther García-García1,2,3, Albert Coll-Manzano1,2,3, Maria 
Carreras-Caballé1,2,3, Nerea Chaparro-Cabanillas1,2,3, Mercè 
Masana1,2,3, Jordi Alberch1,2,3 and Manuel J. Rodríguez1,2,3
1. Dept. Biomedical Sciences, Institute of Neurosciences, 
School of Medicine and Health Sciences, Universitat de 
Barcelona, Barcelona, Spain
2. Institut d’Investigacions Biomèdiques August Pi i Sunyer 
(IDIBAPS), Barcelona, Spain
3. Centro de Investigación Biomédica en Red sobre 
Enfermedades Neurodegenerativas (CIBERNED), Madrid, 
Spain.
Abstract
Chorea-acanthocytosis (ChAc) is caused by VPS13A gene 
mutations leading to absence of the chorein protein. ChAc 
patients show adult-onset progressive movement disorders 
and a selective degeneration of the striatum. There is a poor 
knowledge about the localization and function of chorein 
in the brain. The objective of this work is to analyze the 
chorein distribution along the mouse brain and to evaluate 
the subcellular localization of chorein in cortical primary 
cultures. Thus, we evaluated the distribution of chorein 
mRNA and protein in mouse brain tissue by fluorescence 
in-situ hybridization and immunohistochemistry. This 
analysis showed a widespread distribution of chorein 
along the mouse brain, with different staining intensity 
profiles between nuclei. In general, the mRNA localization 
resembled that of the protein one with an enrichment in 
the pons and cerebellum. The hippocampus presented 
high chorein labelling in the pyramidal layer and in the 
granular layer of dentate gyrus. We found moderate 
staining in the cortex and in the most thalamic and 
hypothalamic nuclei. Interestengly, we found weak 
staining in the basal ganglia nuclei whereas we found no 
staining in white matter structures. Not only neurons but 
also some glial cells expressed chorein. Then, we evaluated 
the subcellular localization of chorein in cortical primary 
cultures by immunocytochemistry and in cerebral cortex 
by synaptosomal isolation. We found chorein in the soma 
but also in neurites, interacting with both the endoplasmic 
reticulum and mitochondria. However, we found no chorein 
staining within the dendritic spines of cortical neurons in 
culture. Finally, Chorein was present but no significantly 
enriched in the crude synaptosomal fraction of cerebral 
cortex tissue. Deciphering the chorein localization in the 
brain constitutes the first step to understand its role in the 
ChAc pathophysiology. 
Funded by SAF2017-88076-R, Ministerio de Ciencia, 
Innovación y Universidades and Fundación ChAc.
POSTER # 3
Normal chorein signal on red cell 
membrane Western blotting in VPS13A 
disease
Gabriel Miltenberger-Miltenyi1, Benedikt Bader1, Antonio 
Velayos-Baeza2, Lothar Burghaus3, Paul Goldsmith4, 
Angela Abicht5, Roongroj Bhidayasiri6, Nikhil Balakrishnan7, 
David Simon8, Ruth Walker9, Naomi Lubarr9 and Adrian 
Danek1.
1. Department of Neurology, Ludwig-Maximilians-
Universität München, Munich, Germany.
2. Wellcome Centre for Human Genetics, University of 
Oxford, Oxford, United Kingdom.
3. Klinik für Neurologie, Heilig Geist-Krankenhaus, Köln, 
Germany.
4. Department of Neurology, Royal Victoria Infirmary, 
Newcastle Upon Tyne, UK.
5. Medical Genetics Center, Munich, Germany.
6. Chulalongkorn University, Bangkok, Thailand.
7. Neurosciences Institute, Neurology University, Charlotte, 
NC, USA
8. Department of Neurology, Beth Israel Deaconess Medical 
Center, Harvard Medical School, Boston, Massachusetts, 
USA.
9. Department of Neurology, Mount Sinai School of 
Medicine, New York, NY, USA.
Abstract
VPS13A disease is a rare, autosomal recessively inherited 
neurodegenerative disorder caused by mutations in the 
VPS13A gene, coding for the chorein protein. Next to DNA 
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studies, Western blot (WB) analysis of chorein is of great 
diagnostic value for all suspected cases, in particular when 
quick diagnosis is required or when genetic studies of the 
complex VPS13A gene are not easily available. Dobson-
Stone et al. (2004) showed that the chorein band detected 
by WB of erythrocyte (red blood cell, RBC) membranes was 
absent or severely reduced in VPS13A disease patients, 
with already confirmed VPS13A mutations. Financially 
supported by the Advocacy for Neuroacanthocytosis 
Patients (www.naadvocacy.org) we were able to offer 
the chorein WB for free as of 2006. Up to now we have 
received more than 700 samples from patients with a 
clinical suspicion of chorea-acanthocytosis. In 194 cases, 
we confirmed a diagnosis of VPS13A disease because 
of absence or clearly reduced levels of RBC membrane 
chorein, using a polyclonal antiserum (anti-chor1) against 
the N-terminal region of chorein (Dobsone-Stone et al. 
2004). Interestingly, a number of patients showing normal 
chorein levels presented with highly suggestive clinical 
features of VPS13A disease; a genetic follow-up has been 
started in a number of cases and, so far, pathogenic 
mutations in VPS13A have been detected in six of them.
Our observations confirm that the chorein WB has 
less than 100% sensitivity for the diagnosis of VPS13A 
disease. Thus, they stress the need to follow up on 
patients with clinical features highly suggestive of 
VPS13A disease even if chorein WB appeared normal. 
These observations may relate to properties of the 
antibody used. Quantitative analyses of the chorein 
bands are pending. Studying these cases can provide 
valuable insight about functional domains and stability 
of chorein
POSTER # 4
Novel mutations and findings in a large 
cohort of McLeod neuroacanthocytosis 
patients
Kevin Peikert1, Beate Schlotter-Weigel2; Federica 
Montagnese2, Peter Reilich2, Carsten Saft3, Franz Marxreiter4,5, 
Zacharias Kohl6, Stefan Evers7,8, Wolfgang von Kalckreuth9, 
Carsten Buhmann10, Beate Mayer11, Ernst Walther12, Armin 
Orth13, Manfred Hoenig14, Krassen Nedeltchev15, Wolfgang 
N Löscher16, Hans H Jung17, Maja Mattle-Greminger18, Beat 
M. Frey18, Andreas Hermann1,19,20 and Adrian Danek21.
1. Translational Neurodegeneration Section “Albrecht-
Kossel”, Department of Neurology, University Medical 
Center Rostock, University of Rostock, Rostock, Germany. 
2. Friedrich-Baur-Institut, Neurologische Klinik, Ludwig-
Maximilians-Universität München, Germany.
3. Department of Neurology, St. Josef Hospital, 
Gudrunstraße 56, 44791 Bochum, Germany.
4. Department of Molecular Neurology, University Hospital 
Erlangen, Schwabachanlage 6, 91054 Erlangen 
5. Center for Rare Movement Disorders, University Hospital 
Erlangen,  Schwabachanlage 6, 91054 Erlangen 
6. Department of Neurology, University of Regensburg, 
Regensburg, Germany.
7. Medical Faculty, University of Münster, Münster, 
Germany.
8. Department of Neurology, Lindenbrunn Hospital, 
Coppenbrügge, Germany.
9. Praxis für Neurologie und Psychiatrie an der 
Johanneskirche, Freiburg, Germany.
10. Department of Neurology, University Medical Center 
Hamburg-Eppendorf, Martinistraße 52, 20246 Hamburg, 
Germany.
11. Institute of Transfusion Medicine, Charité – 
Universitätsmedizin Berlin, corporate member of Freie 
Universität Berlin, Humboldt-Universität zu Berlin, and 
Berlin Institute of Health, Berlin, Germany.
12. Zentrum für Neurologie und Neurorehabilitation, Schön 
Klinik Hamburg Eilbek, Hamburg, Germany.
13. Klinik für Neurologie, Knappschaftsklinikum Saar, 
Püttlingen, Germany.
14. Department of Pediatrics, University Medical Center 
Ulm, Ulm, Germany.
15. Department of Neurology, Kantonsspital Aarau, Aarau, 
Switzerland.
16. Department of Neurology, Medical University of 
Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria.
17. Departement of Neurology, University Hospital and 
University of Zurich, Zurich, Switzerland.
18. Blood Transfusion Service Zürich, Swiss Red Cross (SRC), 
Zurich-Schlieren, Switzerland.
19. DZNE, German Center for Neurodegenerative Diseases, 
Research Site Rostock/Greifswald, Rostock, Germany.
20. Center for Transdisciplinary Neurosciences Rostock 
(CTNR), University Medical Center Rostock, University of 
Rostock, Rostock, Germany.
21. Neurologische Klinik und Poliklinik, Ludwig-Maximilians-
Universität München, Germany.
Abstract
McLeod syndrome (MLS) is an ultra-rare neurodegenerative 
X-linked disease caused by mutations in the XK gene, 
classified as one of the core neuroacanthocytosis 
syndromes. This is a retrospective and prospective 
analysis of genotype and phenotype of sixteen cases. We 
longitudinally characterized the second largest cohort 
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published up to date and identified novel mutations in the 
XK gene and a novel contiguous gene deletion including 
the PRRG1 gene. Furthermore, we describe two cases with 
contiguous gene deletions including the XK and CYBB 
gene leading to X-linked chronic granulomatous disease 
in the childhood. This study confirms core features of MLS 
such as combination of movement disorder with neuro/
myopathy and neuropsychiatric impairment, overall late 
onset, cardiac involvement, hyper-CK-emia, but describes 
obstructive sleep apnea and childhood occurrence of 
epileptic seizures as potentially novel aspects. Our study 
expands the limited knowledge on the variable course of 
the disease, different clinical phenotypes and the genetic 
spectrum.
POSTER # 5
Targeting copper homeostasis improves 
functioning of vps13∆. yeast mutant cells, 
a model of VPS13-related diseases
Piotr Soczewka1, Déborah Tribouillard-Tanvier2,3, Jean-Paul 
di Rago2, Teresa Zoladek1, Joanna Kaminska1
1. lnstitute of Biochemistry and Biophysics Polish Academy 
of Science, 02-106 Warsaw, Poland.
2. IBGC, UMR 5095, CNRS, Universilé de Bordeaux, F-33000 
Bordeaux, France.
3. Institut National de la Santé et de la Recherche Médicale 
(INSERM),F-33077 Bordeaux, France.
Abstract
Ion homeostasis is crucial for organism functioning, and 
its alterations may cause diseases. For example, copper 
insufficiency and overload are associated with Menkes 
and Wilson’s diseases, respectively, and iron imbalance is 
observed in Parkinson’s and Alzheimer’s diseases. To better 
understand human diseases, Saccharomyces cerevisiae 
yeast are used as a model organism. In our studies, we 
used the vps13D yeast strain as a model of rare neurological 
diseases caused by mutations in VPS13A-D genes. In this 
work, we show that overexpression of genes encoding 
copper transporters CTR1, CTR3, and CCC2, or the addition 
of copper salt to the medium, improved functioning of the 
vps13D mutant. We show that their mechanism of action, 
at least partially, depends on increasing iron content in 
the cells by the copper-dependent iron uptake system. 
Finally, we present that treatment with copper ionophores, 
disulfiram. elesclomol, and sodium pyrithione, also resulted 
in alleviation of the defects observed in vps13D cells. Our 
study points at copper and iron homeostasis as a potential 
therapeutic target for further investigation in higher 
eukaryotic models of VPS13-related diseases. 
Soczewka, P.; Tribouillard-Tanvier, D.; di Rago, J.-P.; Zoladek, 
T.; Kaminska, J. lnt. J. Mol. Sci. 2021, 22, 2248. https://doi.
org/10.3390/ijms22052248
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